SRTS vs. BWAY, BLUA, ALUR, STIM, KRMD, PDEX, NVNO, MGRM, SEPA, and HSAQ
Should you be buying Sensus Healthcare stock or one of its competitors? The main competitors of Sensus Healthcare include BrainsWay (BWAY), BlueRiver Acquisition (BLUA), Allurion Technologies (ALUR), Neuronetics (STIM), KORU Medical Systems (KRMD), Pro-Dex (PDEX), enVVeno Medical (NVNO), Monogram Orthopaedics (MGRM), SEP Acquisition (SEPA), and Health Sciences Acquisitions Co. 2 (HSAQ). These companies are all part of the "surgical & medical instruments" industry.
BrainsWay (NASDAQ:BWAY) and Sensus Healthcare (NASDAQ:SRTS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, community ranking, dividends, analyst recommendations, institutional ownership and media sentiment.
BrainsWay presently has a consensus target price of $13.00, suggesting a potential upside of 141.19%. Sensus Healthcare has a consensus target price of $10.00, suggesting a potential upside of 62.34%. Given Sensus Healthcare's higher possible upside, research analysts clearly believe BrainsWay is more favorable than Sensus Healthcare.
Sensus Healthcare has a net margin of 14.70% compared to Sensus Healthcare's net margin of -4.83%. BrainsWay's return on equity of 9.76% beat Sensus Healthcare's return on equity.
In the previous week, Sensus Healthcare had 11 more articles in the media than BrainsWay. MarketBeat recorded 14 mentions for Sensus Healthcare and 3 mentions for BrainsWay. BrainsWay's average media sentiment score of 0.97 beat Sensus Healthcare's score of 0.70 indicating that Sensus Healthcare is being referred to more favorably in the news media.
Sensus Healthcare has lower revenue, but higher earnings than BrainsWay. BrainsWay is trading at a lower price-to-earnings ratio than Sensus Healthcare, indicating that it is currently the more affordable of the two stocks.
30.1% of BrainsWay shares are held by institutional investors. Comparatively, 25.3% of Sensus Healthcare shares are held by institutional investors. 19.0% of BrainsWay shares are held by company insiders. Comparatively, 11.1% of Sensus Healthcare shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Sensus Healthcare received 116 more outperform votes than BrainsWay when rated by MarketBeat users. Likewise, 67.94% of users gave Sensus Healthcare an outperform vote while only 64.58% of users gave BrainsWay an outperform vote.
BrainsWay has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Comparatively, Sensus Healthcare has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500.
Summary
Sensus Healthcare beats BrainsWay on 12 of the 17 factors compared between the two stocks.
Get Sensus Healthcare News Delivered to You Automatically
Sign up to receive the latest news and ratings for SRTS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SRTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sensus Healthcare Competitors List
Related Companies and Tools
